History
The Saarland University Medical Center (Universitätsklinikum des Saarlandes - UKS) was founded in 1947 on the site of the former Palatine Sanatorium and Nursing Home, originally was founded in 1909. Today, the entire spectrum of medicine is offered on a campus harmoniously embedded in the surrounding forest. The UKS plays a leading role in medical teaching, research and patient care in the Saarland and bordering Rhineland Palatinate provinces, as well as in the neighboring France and Luxembourg regions.
Profile
The UKS Center of Integrated Oncology and Palliative Medicine (UKS Zentrum für Integrierte Onkologie und Palliativmedizin) is incorporated within the Saarland University Medical Center and is responsible for the treatment of haematological malignancies and solid tumours. On our oncology ward (68 beds) and palliative care ward (12 beds) as well as in our outpatient offices (8 in total), we provide optimised, academic-level interdisciplinary care through close cooperation of the following departments:
- Department of Haematology, Oncology, Rheumatology and Clinical Immunology
- Centre for Cross-age Palliative Care and Paediatric Pain Management
Specialities
Our centre includes consultants of various specialities including haemato-oncology, paediatrics, internal medicine, general practice and anaesthesiology. Besides broad haemato-oncologic and palliative care, specialised treatment forms are offered including psychological support, pastoral/spiritual support, animal-assisted therapy, music and art therapy, as well as acupuncture.
Palliative and Supportive Care
Supportive and palliative care plays an important role in the management of haematological and oncological malignancies. Many patients with cancer do not require immediately any kind of direct anti-tumour treatment. Others, although it is indicated, cannot receive any or have discontinued therapy for a variety of reasons. As a primary care provider, we accompany and support each of those patients through every stage of their disease. This may mean regular administration of blood products, haematopoietic growth factors, pharmaceutical and interventional symptom management and control, psychological, social support, and close monitoring for changes in status. For each patient, an individualised treatment management plan is prepared.
Additional contact person:
Dr. med. Christiane Keller
Christiane.keller@uks.eu
Last update: July 2024
